Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population–based case–control study

Henrik Falhammar a, b, Jonatan D. Lindh c, Jan Calissendorff a, b, Jakob Skov a, David Nathanson b, d, Buster Mannheimer d

https://doi.org/10.1016/j.ejim.2018.08.012

Highlights

• Newly initiated PPIs and hospitalization due to hyponatremia was associated.
• Lansoprazole was an exception with no association found.
• In severe hyponatremia with newly initiated PPI, consider an alternative.
• If the indication for PPI use remains, lansoprazole could here be an option.
• Severe hyponatremia was not associated with ongoing PPI treatment.

Abstract

Background

Small observational studies and case reports have indicated that proton pump inhibitors (PPIs) may cause hyponatremia. Whether there is a difference between the individual PPIs is yet unknown. Since PPIs are one of the most commonly prescribed groups of drugs, even a rare adverse reaction may have large implications. The objective was to study the association between...
 Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population–based case–control study - ScienceDirect

PPIs and hospitalization due to hyponatremia.

Methods

This register–based case–control study was based on the general Swedish population. Patients hospitalized with a principal diagnosis of hyponatremia (n = 14,359) were compared to matched controls (n = 57,383). The association between newly initiated (≤90 days) and ongoing PPI use was explored using multivariable logistic regression adjusting for concomitant drugs, medical conditions, previous hospitalizations and socioeconomic factors.

Results

Adjusted ORs (95%CI) for hospitalization due to hyponatremia, compared to controls, were for newly initiated: omeprazole 2.67 (2.37–3.01); pantoprazole 2.06 (1.32–3.19); lansoprazole 1.19 (0.72–1.94); esomeprazole 2.89 (2.21–3.79) and any PPI 2.78 (2.48–3.11). Only one individual had been newly initiated on rabeprazole and had been hospitalized due to hyponatremia. Adjusted ORs (95%CI) for individuals with ongoing treatment were for: omeprazole 1.04 (0.97–1.11); pantoprazole 0.81 (0.62–1.05); lansoprazole 0.90 (0.70–1.15); rabeprazole 3.34 (0.84–11.43); esomeprazole 1.12 (0.94–1.33) and any PPI 1.04 (0.98–1.11).

Conclusions

With the exception of lansoprazole, this study suggests an association between any newly initiated PPI-treatment and hospitalization due to hyponatremia. Ongoing PPI use was not associated with an increased risk.

Keywords

Omeprazole, ; Pantoprazole, ; Lansoprazole, ; Rabeprazole, ; Esomeprazole, ; Hyponatremia, ; SIADH, ; Adverse reaction, ;